Recently, Leshchiner et al. [51] performed experiments using small-molecule inhibitors that directly targeted CARD9, and registered an attenuation of IKK phosphorylation after CARD9 inhibition in the context of inflammatory bowel disease. Here, CARD9 is linked to inflammatory bowel disease.